Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies

J Thorac Oncol. 2013 Aug;8(8):e75-8. doi: 10.1097/JTO.0b013e318293d96f.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology*
  • Adenocarcinoma of Lung
  • Adult
  • Anaplastic Lymphoma Kinase
  • Cell Transformation, Neoplastic*
  • Crizotinib
  • Drug Resistance, Neoplasm
  • Epithelial-Mesenchymal Transition
  • Gene Rearrangement*
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology*
  • Male
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use*
  • Pyridines / therapeutic use*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Sarcoma / drug therapy*
  • Sarcoma / genetics
  • Sarcoma / pathology

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases